Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
Kyriakos P PapadopoulosNehal LakhaniGerald S FalchookGosia RileyJohan BaeckKaren S BrownGilad GordonLidya LeJudy S WangPublished in: Cancer immunology, immunotherapy : CII (2020)
NCT03790488, December 31 2018.